(1) Uniformity ofsurgical methods.-All the material is provided by Mr. McKissock and Mr. Logue. No two surgeons' methods are identical, but these two know each other's methods very well, and for the present purpose are keeping their treatments as similar as possible.
(2) Strictness and uniformity of histological diagnosis.-In every case in which brain tissue has been obtained for biopsy, one and the same microscope slide is passed round between three pathologists who give their independent opinions on it. Two of the three are always Dr. William Blackwood and Dr. J. W. Whittick, and the third is either Professor Crawford, Dr. W. H. McMenemey or Dr. Martin Bodian. Five kinds of histological diagnosis are acceptable for the clinical trial: astrocytoma (or astroblastoma) of grades 1, 2, 3 and 4 in Kernohan's classification, and oligodendroglioma (or oligodendroblastoma). Grades 1 and 2 of astrocytoma are regarded as a single pathological group, grades 3 and 4 (corresponding to glioblastoma in the older terminology) form another single group, and oligodendroglioma forms a third group. Table I shows in detail how the histological reports are sorted into five pathological groups, to which there is added a sixth, for presumed gliomata without biopsy. Opinioni of All three pathologists: "astrocytoma, grade 3" or "astrocytoma, grade 4" (N.B. astroblastomata are counted as astrocytomata) .. .. .. Glioblastoma (G) Two pathologists: as above. Third pathologist: any other kind of glioma .. Glioblastoma (G) All three pathologists: "astrocytoma, grade 1" or "astrocytoma, grade 2".. Astrocytoma (A) Two pathologists: as above. Third pathologist: any other kind of glioma .. Astrocytoma (A) All three pathologists: "oligodendroglioma" or "oligodendroblastoma" .. Oligodendroglioma (0) Two pathologists: as above. (3) Exclusion of unsuitable forms of glioma.-We have excluded medulloblastomata, because the evidence for their being radiosensitive is comparatively good; and astrocytomata limited to one cerebellar hemisphere, because the surgeon can completely excise them, leaving no tumour tissue to need irradiation. Ependymomata are believed by some people to resemble medulloblastomata in being especially radiosensitive, and are in any case rare, and so we have excluded them also.
(4) A moderately simple classification of cases.-When it comes to classifying, zeal has to be restrained because of time and space. Table II is a list of prognostic features, each perfectly reasonable in itself; if due regard were paid to all of them, the number of ultimate subdivisions would be over a thousand million, or about half the present population of the globe. Table III shows the actual classification adopted for the present enquiry. One could hardly do less than divide patients, as here, by sex, into two age groups, by two degrees of surgery and into four Main pathological groups; but, as we have seen, two more subsidiary groups are needed, and the outcome is 44 ultimate subdivisions. That is not quite so bad as it sounds. Table IV shows that after the first 12 months of the enquiry, 16 of the possible 44 subdivisions were still empty, and some subdivisions already contained a substantial number of cases. At the present rate, for example, the subdivision M S L G, at the end of another two years, will probably contain enough cases to yield statistically reliable conclusions by itself. (5) Uniformity of starting point for measurement of survival.-Each patient's survival is measured from the day of his principal operation; that is ventriculography, if that was the most that was done in the way of surgery; or burr-hole biopsy, if that was the most; or craniotomy, if that also was done.
(6) A fixed minimum period ofsurvivalfor inclusion in the series.-If one were to include every patient who had lived, say, 4 weeks after operation, the radiotherapist would justly protest that many so-called irradiated patients had died after only a negligible total dose of X-rays. On the other hand, if one included only those who had lived, say, 12 or 16 weeks after operation, in order that every single irradiated patient in the series should be quite completely irradiated, then the total number of cases would be needlessly reduced. In this clinical trial a minimum of 56 days was agreed on as a fair compromise by surgeons, pathologists and radiotherapists. If, as a result of exceptional delays, a patient dies more than 56 days after operation, and yet without his full dose of X-rays, that is considered to be one of the inevitable imperfections of the system of radiotherapy and he is still regarded as an irradiated patient. Full records are kept of the patients who die in less than 56 days, so that it will be possible to alter the minimum period retrospectively if we wish. M or F J or S ..
(7) A simple method of determining whether a given patient shall be irradiated or not.-Within each ultimate subdivision, the chronologically first patient is intended for irradiation, the second is unirradiated and so on alternately. I say "intended for irradiation" because of course any patient may die too soon for it.
(8) Comparative uniformity of methods ofradiotherapy.-All irradiation is carried out at the Royal Cancer Hospital, Chelsea, by Dr. Simon Kramer on behalf of Professor Smithers. Beyond that, no uniformity is possible; one cannot standardize the total dose of X-rays, nor the number of separate doses, nor even the type of apparatus used. Like the surgeon, the radiotherapist must have a free hand in treating each individual according to his judgment; but we have at least secured that similar cases will be treated by very similar methods.
(9) Uniformity offollow-up.-The dates aimed at for follow-up are 56 days after operation, 112 days after operation, and so on every 56 days. Patients are never seen before the correct date, and usually not more than a week or two after it. Whenever it is possible, the irradiated and the unirradiated are interviewed and examined on the same day and by the same two observers together, namely by Dr. Simon Kramer and myself. Points to which we pay particular attention are whether the patient is at his former work and getting his former wages, whether pre-operative symptoms and signs persist, whether the scalp over the burr-holes is sunken or bulging, and the visual acuity. Some patients, needless to say, live in remote parts of the British Isles and are too ill to be brought to London; and one, who is very well, has gone to live in Australia. So far, however, no patient has been entirely lost sight of, and no death has occurred without our ascertaining its date fairly accurately. One unirradiated patient, despite a request to the contrary, has been given radiotherapy elsewhere and has had to be rejected.
I wish to thank all the experts whom I have already named, and also those physicians'who have kindly allowed their patients to be included in the trial. I owe a special debt of gratitude to Dr. Marion Smith, my collaborator in an earlier clinical study of 300 gliomata treated by Mr. McKissock. That study showed us the lack of evidence about the effects of X-rays on gliomata, and gave me some useful experience of the problems which still face us. The present enquiry is being aided by a generous grant from the Medical Research Council.
Finally, I trust it will be understood that at this stage I can say nothing whatever about results.
